Tagged with

Genzyme de Colombia S.A. What is the role, significance, and importance of the Colombian market within the larger global strategy of Genzyme international? Colombia is a very important country because we have a market with a well developed, and in that way different, health system from other countries in the Andean region. Of course…

Novo Nordisk Brazil Diabetes affects an estimated 6 million Brazilians, a figure which is expected to double by 2025, in line with many other developing nations. Like many other “rich-country” diseases, there is a tendency for its sudden prevalence to result in less-than-adequate treatment profiles. What have you observed here in Brazil? The…

Shire Brazil Minister Pimentel recently released the BrasilMaior plan, whose slogan is “Innovate to compete. Compete to grow.” How would you recommend the government innovate, compete, and grow in the pharmaceutical industry here in Brazil? First of all, the government must keep the status quo to respect intellectual property. This is imperative,…

Chamber of Commerce “Polish Pharmacy” The pharmaceutical industry market growth, including generics and originator drugs, is today steady and sustainable. The market size is over 5 billion Euros which makes Poland the 6th biggest market in Europe. What are the competitive advantages do you see in the Polish market compared to other European countries? First,…

Romanian Association of International Drug Manufacturers (ARPIM) While, today, you are in charge of voicing the concerns of the innovators in the country, let us first take a step back and see what attracted these companies to Romania in the first place. Can you tell our readers more about the key factors of attraction in that sense?…

Merck Serono As a majority family owned group, Merck is also the oldest pharmaceutical company in the world and known throughout the market for its long-term vision. How would you compare this vision and company culture with the recently merged Serono´s and how has this affected the overall long-term strategy of the…

Novartis France You worked for many years in emerging markets, especially in Latin America, but also in neighbor countries such as Spain. How these previous experiences in very different markets can now help you direct the world’s third largest pharmaceutical market? Experiencing different patterns, trends and types of businesses gives you a…

When we interviewed you four years ago, you gave us a picture of the industry. How has that picture changed since then? We can start with the regulatory picture. In the past four years, Brazil went through a transition from an old system to a new system consistent with international…

Bristol-Myers Squibb France BMS recently announced divesting from their facilities in Epernon and Meymac but at the same time reinforcing manufacturing in Agen. Could you speak to strategy of this restructuring within France and what it means for the future? In the larger context of the industry, we are at a crossroads where…

Pfizer Chile Last year Pfizer consolidated its position as the world´s largest global pharmaceutical company by acquiring Wyeth, of which you were previously the General Manager here in Chile. Given your privileged position as head of the combined company, how would you evaluate the integration of the two companies in Chile, and…

Many readers may find it counterintuitive that SINDUSFARMA, which represents syndicates, is organized by a team of management executives. Historically, these two groups tend to be in opposition. Can you explain this relationship? Until 2004, relations between unions and industry were undertaken by FIESP. At that time, they also took…

Roche Chile How would you assess Roche’s performance in Chile since its establishment and how has your portfolio developed in the Chilean market? Next year marks Roche’s 40th anniversary in Chile, which makes this affiliate younger than most of the other Latin American ones. This is mainly because from the beginning the…